The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma / 결핵
Tuberculosis and Respiratory Diseases
;
: 211-216, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-761950
ABSTRACT
BACKGROUND:
Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients.METHODS:
Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles.RESULTS:
A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient.CONCLUSION:
Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Citas y Horarios
/
Carcinoma de Células Escamosas
/
Incidencia
/
Resultado del Tratamiento
/
Carcinoma de Pulmón de Células no Pequeñas
/
Supervivencia sin Enfermedad
/
Quimioterapia
/
Células Epiteliales
/
Estudio Clínico
/
Pulmón
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
Límite:
Anciano
/
Humanos
Idioma:
Inglés
Revista:
Tuberculosis and Respiratory Diseases
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS